JNJ vs SLP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Simulations Plus (SLP) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating a deteriorating financial trend. While the company maintains an exceptionally clean balance sheet with zero debt and high liquidity (Current Ratio 5.47), this is offset by a disastrous profit margin of -77.96% and a long-term price collapse of -76.6% over five years. The valuation is problematic, with a PEG ratio of 9.88 suggesting the stock is significantly overvalued relative to its growth. Despite optimistic analyst price targets, the deterministic data and bearish insider sentiment point to continued instability.
Compare Another Pair
Related Comparisons
JNJ vs SLP: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Simulations Plus, Inc. (SLP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.